CA2475123A1 - Desolvating solvates of atorvastatin hemi-calcium - Google Patents

Desolvating solvates of atorvastatin hemi-calcium Download PDF

Info

Publication number
CA2475123A1
CA2475123A1 CA002475123A CA2475123A CA2475123A1 CA 2475123 A1 CA2475123 A1 CA 2475123A1 CA 002475123 A CA002475123 A CA 002475123A CA 2475123 A CA2475123 A CA 2475123A CA 2475123 A1 CA2475123 A1 CA 2475123A1
Authority
CA
Canada
Prior art keywords
calcium
organic solvent
atorvastatin hemi
crystalline
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002475123A
Other languages
English (en)
French (fr)
Inventor
Judith Aronhime
Dalia Maidan-Hanoch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2475123A1 publication Critical patent/CA2475123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002475123A 2002-02-19 2003-02-19 Desolvating solvates of atorvastatin hemi-calcium Abandoned CA2475123A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35849702P 2002-02-19 2002-02-19
US60/358,497 2002-02-19
PCT/US2003/005216 WO2003070665A2 (en) 2002-02-19 2003-02-19 Desolvating solvates of atorvastatin hemi-calcium

Publications (1)

Publication Number Publication Date
CA2475123A1 true CA2475123A1 (en) 2003-08-28

Family

ID=27757749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002475123A Abandoned CA2475123A1 (en) 2002-02-19 2003-02-19 Desolvating solvates of atorvastatin hemi-calcium

Country Status (15)

Country Link
US (2) US7122681B2 (enExample)
EP (1) EP1465901A4 (enExample)
JP (4) JP4422488B2 (enExample)
KR (3) KR20040086397A (enExample)
CN (1) CN100379723C (enExample)
AU (1) AU2003213171A1 (enExample)
CA (1) CA2475123A1 (enExample)
HR (1) HRP20040767A2 (enExample)
IL (1) IL163594A0 (enExample)
IS (1) IS7407A (enExample)
MX (1) MXPA04007995A (enExample)
NO (1) NO20043829L (enExample)
PL (1) PL372241A1 (enExample)
WO (1) WO2003070665A2 (enExample)
ZA (1) ZA200406229B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
DE202005020766U1 (de) * 2004-07-22 2006-10-05 Teva Pharmaceutical Industries Ltd. Neue Kristallformen von Atorvastatin-Hemi-Calcium
MX2007002248A (es) * 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
JP2008514722A (ja) * 2004-09-30 2008-05-08 ドクター レディズ ラボラトリーズ リミテッド 非結晶性アトルバスタチンカルシウム
US20090215855A1 (en) * 2005-04-08 2009-08-27 Jozsef Barkoczy New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form
EP1966133A2 (en) * 2005-12-13 2008-09-10 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US20070265456A1 (en) * 2006-05-09 2007-11-15 Judith Aronhime Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IT1390848B1 (it) * 2008-07-31 2011-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
JP6563017B2 (ja) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11261183B2 (en) * 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
LT3630744T (lt) 2017-05-23 2023-03-10 H. Lundbeck A/S Pirazolo magl inhibitoriai
KR102839500B1 (ko) 2018-08-22 2025-07-28 아셰뉴론 에스아 글리코시다제 억제제로서 유용한 피페라진 유도체의 숙시네이트 및 푸마레이트 산 부가염

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444129A (en) * 1891-01-06 Henry l
US4444129A (en) * 1982-11-05 1984-04-24 Lecorp Method of drying fine coal particles
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
JPS59167676A (ja) * 1983-03-11 1984-09-21 株式会社　大川原製作所 多室型流動層乾燥機
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
JP3296564B2 (ja) * 1995-07-17 2002-07-02 ワーナー−ランバート・コンパニー 結晶性の〔Ｒ−（Ｒ▲上＊▼，Ｒ▲上＊▼）〕−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−〔（フェニルアミノ）カルボニル〕−１Ｈ−ピロール−１−ヘプタン酸ヘミカルシウム塩（アトルバスタチン）
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
KR20020063190A (ko) 1999-11-17 2002-08-01 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 칼슘의 다형태
WO2001044181A1 (en) 1999-12-17 2001-06-21 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
ATE309985T1 (de) 1999-12-17 2005-12-15 Pfizer Science & Tech Ltd Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
EP1345896B1 (en) 2000-12-27 2009-01-07 Teva Pharmaceutical Industries Limited Crystalline forms of atorvastatin
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (enExample) 2001-04-11 2003-08-09 Cadila Heathcare Ltd
CA2450111C (en) * 2001-06-29 2006-02-07 Warner-Lambert Company Llc Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)
CZ2004126A3 (cs) 2001-07-30 2004-12-15 Dr. Reddy's Laboratories Limited Krystalické formy VI. A VII. vápenaté soli atorvastatinu
CA2456095C (en) 2001-08-31 2010-05-11 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
CA2475864A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix

Also Published As

Publication number Publication date
ZA200406229B (en) 2006-06-28
IS7407A (is) 2004-08-17
HRP20040767A2 (en) 2004-12-31
MXPA04007995A (es) 2004-11-26
JP2013136630A (ja) 2013-07-11
AU2003213171A1 (en) 2003-09-09
CN100379723C (zh) 2008-04-09
WO2003070665A2 (en) 2003-08-28
EP1465901A2 (en) 2004-10-13
PL372241A1 (en) 2005-07-11
US7122681B2 (en) 2006-10-17
JP2009143957A (ja) 2009-07-02
US20030216584A1 (en) 2003-11-20
IL163594A0 (en) 2005-12-18
US20070027328A1 (en) 2007-02-01
NO20043829L (no) 2004-09-13
KR20090045420A (ko) 2009-05-07
WO2003070665A3 (en) 2004-02-12
JP2005523285A (ja) 2005-08-04
EP1465901A4 (en) 2006-02-01
JP4422488B2 (ja) 2010-02-24
KR20090045419A (ko) 2009-05-07
CN1633439A (zh) 2005-06-29
KR20040086397A (ko) 2004-10-08
JP2009235100A (ja) 2009-10-15

Similar Documents

Publication Publication Date Title
US7122681B2 (en) Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
EP3969443B1 (en) Solid state forms of tafamidis and salts thereof
EP3938363A1 (en) Solid state forms of ripretinib
WO2022261410A1 (en) Solid state forms of lanifibranor and process for preparation thereof
WO2019094409A1 (en) Salts and solid state forms of ozanimod
EP3867264A1 (en) Solid state forms of voclosporin
US20100260851A1 (en) Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
EP4433461A1 (en) Solid state form of tafamidis
US20080139623A1 (en) Amorphous and crystalline forms of pantoprazole magnesium salt
EP4073058A1 (en) Solid state form of lemborexant
EP4482834A1 (en) Solid state forms of danicopan and process thereof
WO2023287938A1 (en) Solid state forms of amcenestrant
WO2025224678A1 (en) Solid state forms of milvexian and process for preparation thereof
WO2024062344A1 (en) Solid state forms of mesdopetam and salts therof
WO2025017530A1 (en) Solid state forms of buntanetap and process for preparation thereof
WO2025141467A1 (en) Solid state forms of lorundrostat and process thereof
EP1768969B1 (en) Crystalline mycophenolate sodium
WO2020154581A1 (en) Solid state forms of fedovapagon-salicyclic acid co-crystal
EA050039B1 (ru) Твердые формы мавакамтена и способ их получения
WO2007038677A2 (en) Methods for preparation of ladostigil tartrate crystalline form a1

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued